misleading statements

Rosen Law Firm seeks lead plaintiffs for PomDoctor securities class action alleging fraud, insider dumping, and misleading statements. $100K+ loss threshold for investor eligibility.

Rosen Law Firm notifies Inovio investors of securities class action with April 7, 2026 lead plaintiff deadline, citing alleged false statements on manufacturing and regulatory matters.

Rosen Law Firm sues Franklin BSP Realty Trust for allegedly misleading investors about dividend sustainability. Lead plaintiff deadline set for April 27, 2026.

Ramaco Resources faces securities lawsuit alleging false statements about Brook Mine operations. Investors who purchased stock July-October 2025 may join class action litigation.

Rosen Law Firm sues Corcept Therapeutics for allegedly making misleading statements about clinical trial data and FDA approval prospects for its relacorilant drug candidate.

Corcept faces securities lawsuit over misleading relacorilant claims. FDA rejected the drug, triggering 50% stock decline and $3.6B market cap loss.

BellRing Brands faces securities lawsuit alleging executives misrepresented 2025 sales drivers, attributing growth to retail inventory builds rather than consumer demand. Stock fell 33% after retailers reduced excess inventory.

Class action lawsuits filed against Lakeland Industries and Navan Inc. allege misleading disclosures. Lead plaintiff deadline is April 24, 2026.

Ramaco Resources faces class action lawsuit alleging executives made false statements about Brook Mine operations, claiming mining activity had commenced when it hadn't.

REGENXBIO faces securities lawsuit alleging misleading statements about RGX-111 gene therapy. Lead plaintiff deadline extended to April 14, 2026.

NuScale Power faces shareholder lawsuit alleging false statements about ENTRA1 partnership qualifications and undisclosed risks. Stock dropped 12% after revealing $495M payment and $532M quarterly loss.

Schall Law Firm investigates Oddity Tech after 49% stock plunge following Q4 results. Probe examines whether investors were adequately informed of advertising partner risks.

Class action lawsuit filed against uniQure for allegedly making false statements about FDA approval status and BLA submission timelines, misleading investors.

Varonis Systems faces securities lawsuit alleging executives failed to disclose weakening renewal rates and overstated SaaS transition progress, leading to 48% stock decline and $3.8 billion market cap loss.

Corcept Therapeutics faces securities lawsuit alleging it misrepresented relacorilant's FDA approval prospects, causing stock to plunge 50% after regulatory rejection.

AMC faces class action lawsuit alleging it misled investors about Preferred Equity Unit rights, excluding APE holders from a 2023 dividend distribution through undisclosed technical loopholes.

Fermi Inc. faces securities class action over alleged false statements regarding Project Matador campus development and undisclosed single-tenant dependency risks.

Richtech Robotics faces class action lawsuit for allegedly misrepresenting Microsoft partnership. Stock fell 20.9% after Microsoft clarified the relationship wasn't a commercial partnership.

Inovio Pharmaceuticals faces class action lawsuit over alleged false statements regarding manufacturing defects and regulatory prospects after FDA rejected accelerated approval, causing 24% stock decline.

Agilon Health faces class action lawsuit over false 2025 financial guidance. Lead plaintiff deadline set for March 2, 2026; eligible investors urged to apply.